Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 14/20 | 0.63 |
| ▸ | PGR | P06401 | 13/20 | 0.63 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | SHBG | P04278 | 2/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5700431 | 1.00 | AR (0.63) | ARPGRNR3C2MEN1CYP3A4 | |
| SCHEMBL5700301 | 0.92 | AR (0.61) | ARPGRNR3C2MEN1CYP3A4 | |
| SCHEMBL5700305 | 0.92 | AR (0.61) | ARPGRNR3C2MEN1CYP3A4 | |
| SCHEMBL5700326 | 0.85 | AR (0.63) | ARPGRNR3C2CYP3A4LMNA | |
| SCHEMBL5700503 | 0.85 | PGR (0.68) | ARPGRNR3C2MEN1CYP3A4 | |
| SCHEMBL5700506 | 0.85 | PGR (0.68) | ARPGRNR3C2MEN1CYP3A4 | |
| SCHEMBL11861418 | 0.82 | PGR (0.73) | ARPGRNR3C2MEN1CYP3A4 | |
| SCHEMBL11861409 | 0.82 | PGR (0.73) | ARPGRNR3C2MEN1CYP3A4 | |
| SCHEMBL12949519 | 0.80 | AR (0.67) | ARPGRNR3C2MEN1CYP3A4 | |
| SCHEMBL5700422 | 0.80 | AR (0.60) | ARPGRNR3C2CYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322660-B1 | 17ALPHA-FLUOROALKYL STEROIDS, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS | SCHERING AG (DE) | 2006-08-30 | — | — | EP | claimed |
| US-20040024231-A1 | 17Alpha fluoroalkyl steroids, method for producing the same and pharmaceutical compositions containing said compounds | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-02-05 | — | — | US | claimed |
| EP-1322660-B1 | 17ALPHA-FLUOROALKYL STEROIDS, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS | SCHERING AG (DE) | 2006-08-30 | — | — | EP | disclosed |
| US-20040024231-A1 | 17Alpha fluoroalkyl steroids, method for producing the same and pharmaceutical compositions containing said compounds | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024231-A1 | 17Alpha fluoroalkyl steroids, method for producing the same and pharmaceutical compositions containing said compounds | CYP17A1, CYP21A2, NR5A1 | AR 60/4885PGR 827/4885NR3C2 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.